City
Epaper

DRDO develops antibody test kit DIPCOVAN for early detection of COVID-19

By ANI | Updated: May 21, 2021 16:45 IST

The Defence Research and Development Organisation (DRDO) has developed an antibody test kit for the early screening of COVID.

Open in App

The Defence Research and Development Organisation (DRDO) has developed an antibody test kit for the early screening of COVID.

DIPCOVAN, the DIPAS-VDx COVID 19 IgG Antibody Microwell ELISA for sero-surveillance has been developed by the Defence Institute of Physiology and Allied Sciences (DIPAS) in association with Delhi-based firm Vanguard Diagnostics Pvt Ltd.

According to DRDO, the kit can detect spike as well as nucleocapsid (S and N) proteins of SARS-CoV-2 virus with a high sensitivity of 97 per cent and specificity of 99 per cent. It was developed indigenously by scientists, followed by extensive validation on over 1000 patient samples at various COVID hospitals in Delhi.

DRDO said three batches of the product were validated for the last one year. The antibody detection kit is approved by the Indian Council of Medical Research (ICMR) in April 2021.

In May 2021, the product received regulatory approval from the Drugs Controller General of India (DCGI) and Central Drugs Standard Control Organisation (CDSCO), Ministry of Health and Family Welfare to manufacture for sale and distribution.

According to DRDO, DIPCOVAN is intended for the qualitative detection of IgG antibodies in human serum or plasma, targeting SARS-CoV-2 related antigens. It offers a significantly faster turn-around time as it requires only 75 minutes to conduct the test without any cross-reactivity with other diseases. The kit has a shelf life of 18 months.

Vanguard Diagnostics Pvt. Ltd is expected to launch the product commercially by the first week of June 2021. Readily available stock at the time of launch will be 100 kits (approximately 10,000 tests) with a production capacity of 500 kits/month after the launch. It is expected to be available at about Rs 75 per test.

The kit is believed to be very useful for understanding COVID-19 epidemiology and assessing an individual's previous SARS-CoV-2 exposure.

Earlier this week, DRDO launched the anti-COVID drug 2-deoxy-D-glucose (2-DG). It has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: delhiindiaDrdoDefence Research And Development OrganisationDefence research & development organisation`delhiDelhi capitalSouth delhi district administrationIndi
Open in App

Related Stories

NationalDelhi Metro Update: Services to Begin Early on Yoga Day for Commuters

NationalSonia Gandhi Health Update: Former Congress President Discharged from Hospital After Treatment for Abdominal Infection

NationalSunjay Kapur Funeral Today in Delhi: Final Rites at Lodhi Road Crematorium at 5 PM; Karisma Kapoor’s Children to Attend

NationalOperation Sindhu: “We Saw Drones, Missiles,” Say Evacuated Students Recounting Life in Iran’s Warzone

NationalDelhi: Fire Breaks Out at Factory in Wazirpur Industrial Area (Watch Video)

National Realted Stories

NationalIt's an anniversary of good governance: PM Modi on 1 year completion of Odisha govt

NationalCabin crew sacking: More trouble brews for Air India amid CBI probe demand

NationalChildren of ‘anti-English’ BJP leaders learn the same language, study abroad: Rahul Gandhi

NationalClassroom case: ED raids 37 locations in Delhi, seizes 322 bank passbooks

NationalLalu Yadav, Tejashwi hit back at PM Modi, demand 20-year report card of NDA govt